Literature DB >> 327086

Infections with two dengue viruses in Greece in the 20th century. Did dengue hemorrhagic fever occur in the 1928 epidemic?

G Papaevangelou, S B Halstead.   

Abstract

From contemporary clinical accounts we hypothesized that the 1928 dengue epidemic in Greece may have been an earlier occurrence of dengue hemorrhagic fiver/dengue shock syndrome (DHF/DSS). To study the possibility that two different dengue viruses may have been involved, serums from 62 Athenians alive during the epidemic were examined for dengue antibodies; 73 per cent showed evidence of prior dengue infection. Monotypic neutralizing antibodies were found to two different dengue viruses, types 1 and 2. A large proportion of the sampled population had evidence of two or more past dengue infections. Since there is no evidence that dengue viruses have been transmitted in Greece since 1928, during the epidemic a very large number of persons immune to one dengue type must have acquired infections with a secon type. The virological criteria for secondary infection DHF/DSS are thus satisfied. Although DHF/DSS is currently restricted to Asia and the Pacific, the Greek oubreak suggests a biological potential for fatal consequences of dengue infections in Caucasians, particularly the elderly.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 327086

Source DB:  PubMed          Journal:  J Trop Med Hyg        ISSN: 0022-5304


  16 in total

1.  Antibody to dengue 1 detected more than 60 years after infection.

Authors:  Allison Imrie; Janet Meeks; Alexandra Gurary; Munkhzul Sukhbaatar; Thang Thua Truong; C Bruce Cropp; Paul Effler
Journal:  Viral Immunol       Date:  2007-12       Impact factor: 2.257

Review 2.  Emergence of the severe syndrome and mortality associated with dengue and dengue-like illness: historical records (1890 to 1950) and their compatibility with current hypotheses on the shift of disease manifestation.

Authors:  Goro Kuno
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

3.  Sequential immunization induces strong and broad immunity against all four dengue virus serotypes.

Authors:  Jue Hou; Shubham Shrivastava; Hooi Linn Loo; Lan Hiong Wong; Eng Eong Ooi; Jianzhu Chen
Journal:  NPJ Vaccines       Date:  2020-07-24       Impact factor: 7.344

4.  Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.

Authors:  Anna P Durbin; Alexander Schmidt; Dan Elwood; Kimberli A Wanionek; Janece Lovchik; Bhavin Thumar; Brian R Murphy; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2010-12-14       Impact factor: 5.226

5.  A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2013-01-17       Impact factor: 5.226

Review 6.  Dengue and chikungunya: long-distance spread and outbreaks in naïve areas.

Authors:  Giovanni Rezza
Journal:  Pathog Glob Health       Date:  2014-12-09       Impact factor: 2.894

7.  Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.

Authors:  Julie H McArthur; Anna P Durbin; Jennifer A Marron; Kimberli A Wanionek; Bhavin Thumar; Dennis J Pierro; Alexander C Schmidt; Joseph E Blaney; Brian R Murphy; Stephen S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2008-11       Impact factor: 2.345

8.  Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.

Authors:  Anna P Durbin; Sandra V Mayer; Shannan L Rossi; Irma Y Amaya-Larios; Jose Ramos-Castaneda; Eng Eong Ooi; M Jane Cardosa; Jorge L Munoz-Jordan; Robert B Tesh; William B Messer; Scott C Weaver; Nikos Vasilakis
Journal:  Virology       Date:  2013-02-26       Impact factor: 3.616

9.  Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.

Authors:  Stephen J Thomas; Ananda Nisalak; Kathryn B Anderson; Daniel H Libraty; Siripen Kalayanarooj; David W Vaughn; Robert Putnak; Robert V Gibbons; Richard Jarman; Timothy P Endy
Journal:  Am J Trop Med Hyg       Date:  2009-11       Impact factor: 2.345

10.  Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.

Authors:  Peter F Wright; Anna P Durbin; Stephen S Whitehead; Mine R Ikizler; Susan Henderson; Joseph E Blaney; Bhavin Thumar; Sharon Ankrah; Michael T Rock; Brett A McKinney; Brian R Murphy; Alexander C Schmidt
Journal:  Am J Trop Med Hyg       Date:  2009-11       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.